{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:41:17Z","timestamp":1787920877617,"version":"build-2784847793"},"reference-count":157,"publisher":"Bentham Science Publishers Ltd.","issue":"11","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":160,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Science and Engineering Board, DSTSERB, CRG","doi-asserted-by":"publisher","award":["CRG\/2021\/001009"],"award-info":[{"award-number":["CRG\/2021\/001009"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAR"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Dementia, an international health issue distinguished by the impairment of daily functioning\ndue to cognitive decline, currently affects more than 55 million people worldwide, with\nthe majority residing in low-income and middle-income countries. Globally, dementia entails significant\neconomic burdens in 2019, amounting to a cost of 1.3 trillion US dollars. Informal caregivers\ndevote considerable hours to providing care for those affected. Dementia imposes a greater\ncaregiving and disability-adjusted life-year burden on women. A recent study has established a\ncorrelation between prolonged Proton Pump Inhibitor (PPI) usage and dementia, in addition to\nother neurodegenerative conditions. PPIs are frequently prescribed to treat peptic ulcers and\nGERD (gastroesophageal reflux disease) by decreasing stomach acid secretion. They alleviate\nacid-related symptoms through the inhibition of acid-secreting H+-K+ ATPase. In a number of observational\nstudies, cognitive decline and dementia in the elderly have been linked to the use of\nPPIs. The precise mechanism underlying this relationship is unknown. These drugs might also alter\nthe pH of brain cells, resulting in the accumulation of amyloid-beta (A\u03b2) peptides and the development\nof Alzheimer's disease (AD). Despite the compelling evidence supporting the association\nof PPIs with dementia, the results of studies remain inconsistent. The absence of a correlation\nbetween PPI use and cognitive decline in some studies emphasizes the need for additional research.\nChronic PPI use can conceal underlying conditions, including cancer, celiac disease, vitamin\nB12 deficiency, and renal injury, highlighting dementia risk and the need for further investigations\non cognitive health.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115672050289946240223050737","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T04:08:55Z","timestamp":1709266135000},"page":"739-757","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the\nDementia Connection and Co-morbid Risks"],"prefix":"10.2174","volume":"20","author":[{"given":"Zuber","family":"Khan","sequence":"first","affiliation":[{"name":"Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India (Affiliated to\nIK Gujral Punjab Technical University), Jalandhar, Punjab, 144603, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Mehan","sequence":"additional","affiliation":[{"name":"Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India (Affiliated to\nIK Gujral Punjab Technical University), Jalandhar, Punjab, 144603, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd. Anas","family":"Saifi","sequence":"additional","affiliation":[{"name":"Department of Medical Elementology\nand Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi-110062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghanshyam Das","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of\nPharmaceutics, ISF College of Pharmacy, Moga, Punjab, India (Affiliated to IK Gujral Punjab Technical University),\nJalandhar, Punjab, 144603, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Acharan S.","family":"Narula","sequence":"additional","affiliation":[{"name":"Narula Research, LLC, 107 Boulder Bluff, Chapel Hill, NC27516, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reni","family":"Kalfin","sequence":"additional","affiliation":[{"name":"Institute\nof Neurobiology, Bulgarian Academy of Sciences, Acad. G. Bonchev St., Block 23, Sofia1113, Bulgaria"},{"name":"Department\nof Healthcare, South-West University \u201cNeofitRilski\u201d, Ivan Mihailov St. 66, Blagoevgrad2700, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.amjmed.2018.01.022","volume":"131","author":"Gale S.A.","year":"2018","unstructured":"Gale S.A.; Acar D.; Daffner K.R.; Dementia. Am J Med  2018,131(10),1161-1169","journal-title":"Am J Med"},{"key":"ref=2","unstructured":"Dementia  Available from:  https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia#:~:text=Key%20facts,nearly%2010%20million%20new%20cases"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"e12200","DOI":"10.1002\/trc2.12200","volume":"7","year":"2021","unstructured":"Global mortality from dementia: Application of a new method and results from the global burden of disease study 2019. Alzheimers Dement GBD 2019 Collaborators 2021,7(1),e12200","journal-title":"Alzheimers Dement"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1002\/alz.12901","volume":"19","author":"Wimo A.","year":"2023","unstructured":"Wimo A.; Seeher K.; Cataldi R.; Cyhlarova E.; Dielemann J.L.; Frisell O.; Guerchet M.; J\u00f6nsson L.; Malaha A.K.; Nichols E.; Pedroza P.; Prince M.; Knapp M.; Dua T.; The worldwide costs of dementia in 2019. Alzheimers Dement  Advance online publication2023,19(7),2865-2873","journal-title":"Alzheimers Dement"},{"key":"ref=5","first-page":"14","volume":"35","author":"Mielke M.M.","year":"2018","unstructured":"Mielke M.M.; Sex and gender differences in alzheimer\u2019s disease dementia. Psychiatr Times  2018,35(11),14-17","journal-title":"Psychiatr Times"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"alz.13477","DOI":"10.1002\/alz.13477","author":"Pourhadi N.","year":"2023","unstructured":"Pourhadi N.; Janbek J.; Jensen-Dahm C.; Gasse C.; Laursen T.M.; Waldemar G.; Proton pump inhibitors and dementia: A nationwide population-based study. Alzheimers Dement  2023,alz.13477","journal-title":"Alzheimers Dement"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","volume":"10","author":"Shin J.M.","year":"2008","unstructured":"Shin J.M.; Sachs G.; Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep  2008,10(6),528-534","journal-title":"Curr Gastroenterol Rep"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00228-023-03534-z","volume":"79","author":"Shanika L.G.T.","year":"2023","unstructured":"Shanika L.G.T.; Reynolds A.; Pattison S.; Braund R.; Proton pump inhibitor use: Systematic review of global trends and practices. Eur J Clin Pharmacol  2023,79(9),1159-1172","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=9","author":"Ahmed A.","year":"2023","unstructured":"Ahmed A.; Clarke J.O.; Proton pump inhibitors (PPI). StatPearls  2023","journal-title":"StatPearls"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618809927","volume":"10.","author":"Jaynes M.","year":"2019","unstructured":"Jaynes M.; Kumar A.B.; The risks of long-term use of proton pump inhibitors: A critical review. Ther Adv Drug Saf  2019,10.","journal-title":"Ther Adv Drug Saf"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e14422","DOI":"10.1097\/MD.0000000000014422","volume":"98","author":"Li M.","year":"2019","unstructured":"Li M.; Luo Z.; Yu S.; Tang Z.; Proton pump inhibitor use and risk of dementia. Medicine  2019,98(7),e14422","journal-title":"Medicine"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12916-022-02478-y","volume":"20","author":"Zhang P.","year":"2022","unstructured":"Zhang P.; Li Z.; Chen P.; Zhang A.; Zeng Y.; Zhang X.; Huang Q.; Liu D.; Qi S.; Mao C.; Regular proton pump inhibitor use and incident dementia: Population-based cohort study. BMC Med  2022,20(1),271","journal-title":"BMC Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e0237676","DOI":"10.1371\/journal.pone.0237676","volume":"15","author":"Cooksey R.","year":"2020","unstructured":"Cooksey R.; Kennedy J.; Dennis M.S.; Escott-Price V.; Lyons R.A.; Seaborne M.; Brophy S.; Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS One  2020,15(9),e0237676","journal-title":"PLoS One"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"Masters C.L.","year":"1985","unstructured":"Masters C.L.; Simms G.; Weinman N.A.; Multhaup G.; McDonald B.L.; Beyreuther K.; Amyloid plaque core protein in alzheimer disease and down syndrome. Proc Natl Acad Sci USA  1985,82(12),4245-4249","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2174\/1567205018666210929144740","volume":"18","author":"Papazoglou A.","year":"2021","unstructured":"Papazoglou A.; Arshaad M.I.; Henseler C.; Daubner J.; Broich K.; Haenisch B.; Weiergr\u00e4ber M.; The janus-like association between proton pump inhibitors and dementia. Curr Alzheimer Res  2021,18(6),453-469","journal-title":"Curr Alzheimer Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.3748\/wjg.v19.i16.2560","volume":"19","author":"Ahn J.S.","year":"2013","unstructured":"Ahn J.S.; Eom C.S.; Jeon C.Y.; Park S.M.; Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies. World J Gastroenterol  2013,19(16),2560-2568","journal-title":"World J Gastroenterol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.cgh.2016.05.018","volume":"14","author":"Tran-Duy A.","year":"2016","unstructured":"Tran-Duy A.; Spaetgens B.; Hoes A. W.; de Wit N. J.; Stehouwer C. D.; Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: Systematic review and meta-analysis. Clin Gastroenterol Hepatol  2016,14(12),1706-1719","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1185\/03007995.2015.1047745","volume":"31","author":"Boardman H.F.","year":"2015","unstructured":"Boardman H.F.; Delaney B.C.; Haag S.; Partnership in optimizing management of reflux symptoms: A treatment algorithm for over-the-counter proton-pump inhibitors. Curr Med Res Opin  2015,31(7),1309-1318","journal-title":"Curr Med Res Opin"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.dld.2013.08.128","volume":"46","author":"Lebwohl B.","year":"2014","unstructured":"Lebwohl B.; Spechler S. J.; Wang T. C.; Green P. H.; Ludvigsson J. F.; Use of proton pump inhibitors and subsequent risk of celiac disease. Dig Liver Dis  2014,46(1),36-40","journal-title":"Dig Liver Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/imj.12697","volume":"45","author":"Jung S.B.","year":"2015","unstructured":"Jung S.B.; Nagaraja V.; Kapur A.; Eslick G.D.; Association between vitamin  12 deficiency and long-term use of acid-lowering agents: A systematic review and meta-analysis. Intern Med J  2015,45(4),409-416","journal-title":"Intern Med J"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40620-016-0309-2","volume":"29","author":"Moledina D.G.","year":"2016","unstructured":"Moledina D.G.; Perazella M.A.; PPIs and kidney disease: From AIN to CKD. J Nephrol  2016,29(5),611-616","journal-title":"J Nephrol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","volume":"73","author":"Gomm W.","year":"2016","unstructured":"Gomm W.; von Holt K.; Thom\u00e9 F.; Broich K.; Maier W.; Fink A.; Doblhammer G.; Haenisch B.; Association of proton pump inhibitors with risk of dementia. JAMA Neurol  2016,73(4),410-416","journal-title":"JAMA Neurol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.amsu.2022.104762","volume":"73","author":"Mumtaz H.","year":"2022","unstructured":"Mumtaz H.; Ghafoor B.; Saghir H.; Tariq M.; Dahar K.; Ali S. H.; Waheed S. T.; Syed A. A.; Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol  2022,73(4),410-416","journal-title":"JAMA Neurol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e58837","DOI":"10.1371\/journal.pone.0058837","volume":"8","author":"Badiola N.","year":"2013","unstructured":"Badiola N.; Alcalde V.; Pujol A.; M\u00fcnter L.M.; Multhaup G.; Lle\u00f3 A.; Coma M.; Soler-L\u00f3pez M.; Aloy P.; The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One  2013,8(3),e58837","journal-title":"PLoS One"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1365-2710.2009.01100.x","volume":"35","author":"Fallahzadeh M.K.","year":"2010","unstructured":"Fallahzadeh M.K.; Borhani Haghighi A.; Namazi M.R.; Proton pump inhibitors: Predisposers to alzheimer disease? J Clin Pharm Ther  2010,35(2),125-126","journal-title":"J Clin Pharm Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1001\/jama.2013.280490","volume":"310","author":"Lam J.R.","year":"2013","unstructured":"Lam J.R.; Schneider J.L.; Zhao W.; Corley D.A.; Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA  2013,310(22),2435-2442","journal-title":"JAMA"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","volume":"34","author":"O\u2019Brien R.J.","year":"2011","unstructured":"O\u2019Brien R.J.; Wong P.C.; Amyloid precursor protein processing and Alzheimer\u2019s disease. Annu Rev Neurosci  2011,34(1),185-204","journal-title":"Annu Rev Neurosci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/jgs.15073","volume":"66","author":"Gray S.L.","year":"2018","unstructured":"Gray S.L.; Walker R.L.; Dublin S.; Yu O.; Aiello Bowles E.J.; Anderson M.L.; Crane P.K.; Larson E.B.; Proton pump inhibitor use and dementia risk: Prospective population-based study. J Am Geriatr Soc  2018,66(2),247-253","journal-title":"J Am Geriatr Soc"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jgh.14789","volume":"35","author":"Hussain S.","year":"2020","unstructured":"Hussain S.; Singh A.; Zameer S.; Jamali M.C.; Baxi H.; Rahman S.O.; Alam M.; Altamish M.; Singh A.K.; Anil D.; Hussain M.S.; Ahmad A.; Najmi A.K.; No association between proton pump inhibitor use and risk of dementia: Evidence from a meta-analysis. J Gastroenterol Hepatol  2020,35(1),19-28","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1097\/PRS.0b013e3181f44abc","volume":"126","author":"Song J.W.","year":"2010","unstructured":"Song J.W.; Chung K.C.; Observational studies: Cohort and case-control studies. Plast Reconstr Surg  2010,126(6),2234-2242","journal-title":"Plast Reconstr Surg"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"864882","DOI":"10.3389\/fmed.2022.864882","volume":"9","author":"Shi J.","year":"2022","unstructured":"Shi J.; Norgeot B.; Learning causal effects from observational data in healthcare: A review and summary. Front Med  2022,9,864882","journal-title":"Front Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-009-8104-z","volume":"12","author":"Chow V.W.","year":"2010","unstructured":"Chow V.W.; Mattson M.P.; Wong P.C.; Gleichmann M.; An overview of APP processing enzymes and products. Neuromolecular Med  2010,12(1),1-12","journal-title":"Neuromolecular Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"e20220048","DOI":"10.1590\/1980-5764-dn-2022-0048","volume":"17","author":"Caetano C.","year":"2023","unstructured":"Caetano C.; Veloso M.; Borda S.; Proton pump inhibitors and dementia: What association? Dement Neuropsychol  2023,17,e20220048","journal-title":"Dement Neuropsychol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/2042098617715381","volume":"8","author":"Maes M.L.","year":"2017","unstructured":"Maes M.L.; Fixen D.R.; Linnebur S.A.; Adverse effects of proton-pump inhibitor use in older adults: A review of the evidence. Ther Adv Drug Saf  2017,8(9),273-297","journal-title":"Ther Adv Drug Saf"},{"key":"ref=35","first-page":"169","volume":"14","author":"Ali Khan M.","year":"2018","unstructured":"Ali Khan M.; Howden C.W.; The role of proton pump inhibitors in the management of upper gastrointestinal disorders. Gastroenterol Hepatol  2018,14(3),169-175","journal-title":"Gastroenterol Hepatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","volume":"7","author":"Daneman R.","year":"2015","unstructured":"Daneman R.; Prat A.; The blood-brain barrier. Cold Spring Harb Perspect Biol  2015,7(1),a020412","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3233\/JAD-2010-1262","volume":"19","author":"Rojo L.E.","year":"2010","unstructured":"Rojo L.E.; Alzate-Morales J.; Saavedra I.N.; Davies P.; Maccioni R.B.; Selective interaction of lansoprazole and astemizole with tau polymers: Potential new clinical use in diagnosis of alzheimer\u2019s disease. J Alzheimers Dis  2010,19(2),573-589","journal-title":"J Alzheimers Dis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.4103\/0976-500X.120969","volume":"4","author":"Chimirri S.","year":"2013","unstructured":"Chimirri S.; Aiello R.; Mazzitello C.; Mumoli L.; Palleria C.; Altomonte M.; Citraro R.; De Sarro G.; Vertigo\/dizziness as a Drugs\u2019 adverse reaction. J Pharmacol Pharmacother  2013,4(1_suppl)(Suppl. 1),S104-S109","journal-title":"J Pharmacol Pharmacother"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e12759","DOI":"10.7759\/cureus.12759","volume":"13","author":"Yibirin M.","year":"2021","unstructured":"Yibirin M.; De Oliveira D.; Valera R.; Plitt A.E.; Lutgen S.; Adverse effects associated with proton pump inhibitor use. Cureus  2021,13(1),e12759","journal-title":"Cureus"},{"key":"ref=40","first-page":"28","volume":"17","author":"Appleton J.","year":"2018","unstructured":"Appleton J.; The gut-brain axis: Influence of microbiota on mood and mental health. Integr Med  2018,17(4),28-32","journal-title":"Integr Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.3748\/wjg.v25.i22.2706","volume":"25","author":"Bruno G.","year":"2019","unstructured":"Bruno G.; Zaccari P.; Rocco G.; Scalese G.; Panetta C.; Porowska B.; Pontone S.; Severi C.; Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol  2019,25(22),2706-2719","journal-title":"World J Gastroenterol"},{"key":"ref=42","first-page":"203","volume":"28","author":"Carabotti M.","year":"2015","unstructured":"Carabotti M.; Scirocco A.; Maselli M.A.; Severi C.; The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol  2015,28(2),203-209","journal-title":"Ann Gastroenterol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"240","DOI":"10.21037\/atm.2016.06.14","volume":"4","author":"Wijarnpreecha K.","year":"2016","unstructured":"Wijarnpreecha K.; Thongprayoon C.; Panjawatanan P.; Ungprasert P.; Proton pump inhibitors and risk of dementia. Ann Transl Med  2016,4(12),240","journal-title":"Ann Transl Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.3748\/wjg.v21.i22.6817","volume":"21","author":"Fujimori S.","year":"2015","unstructured":"Fujimori S.; What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol  2015,21(22),6817-6819","journal-title":"World J Gastroenterol"},{"key":"ref=45","volume":"18","author":"Vanderhoof J. A.","year":"2010","unstructured":"Vanderhoof J. A.; Young R. J.; Etiology and pathogenesis of bacterial overgrowth. Clinical manifestations and diagnosis of bacterial overgrowth Treatment of Bacterial Overgrowth  Available from:  http:\/\/www.uptodate.com.2010,18(1)","journal-title":"Clinical manifestations and diagnosis of bacterial overgrowth Treatment of Bacterial Overgrowth"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5152\/tjg.2016.15375","volume":"27","author":"Liang S.","year":"2016","unstructured":"Liang S.; Xu L.; Zhang D.; Wu Z.; Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer. Turk J Gastroenterol  2016,27(3),227-232","journal-title":"Turk J Gastroenterol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1161\/CIRCRESAHA.117.309715","volume":"120","author":"Tang W.H.W.","year":"2017","unstructured":"Tang W.H.W.; Kitai T.; Hazen S.L.; Gut microbiota in cardiovascular health and disease. Circ Res  2017,120(7),1183-1196","journal-title":"Circ Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41598-018-38218-7","volume":"9","author":"Saji N.","year":"2019","unstructured":"Saji N.; Niida S.; Murotani K.; Hisada T.; Tsuduki T.; Sugimoto T.; Kimura A.; Toba K.; Sakurai T.; Analysis of the relationship between the gut microbiome and dementia: A cross-sectional study conducted in Japan. Sci Rep  2019,9(1),1008","journal-title":"Sci Rep"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s13238-016-0338-6","volume":"8","author":"Alkasir R.","year":"2017","unstructured":"Alkasir R.; Li J.; Li X.; Jin M.; Zhu B.; Human gut microbiota: The links with dementia development. Protein Cell  2017,8(2),90-102","journal-title":"Protein Cell"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"13537","DOI":"10.1038\/s41598-017-13601-y","volume":"7","author":"Vogt N.M.","year":"2017","unstructured":"Vogt N.M.; Kerby R.L.; Dill-McFarland K.A.; Harding S.J.; Merluzzi A.P.; Johnson S.C.; Carlsson C.M.; Asthana S.; Zetterberg H.; Blennow K.; Bendlin B.B.; Rey F.E.; Gut microbiome alterations in alzheimer\u2019s disease. Sci Rep  2017,7(1),13537","journal-title":"Sci Rep"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.3748\/wjg.v16.i24.2978","volume":"16","author":"Bures J.","year":"2010","unstructured":"Bures J.; Cyrany J.; Kohoutova D.; F\u00f6rstl M.; Rejchrt S.; Kvetina J.; Vorisek V.; Kopacova M.; Small intestinal bacterial overgrowth syndrome. World J Gastroenterol  2010,16(24),2978-2990","journal-title":"World J Gastroenterol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12877-020-01644-2","volume":"20","author":"Stadlbauer V.","year":"2020","unstructured":"Stadlbauer V.; Engertsberger L.; Komarova I.; Feldbacher N.; Leber B.; Pichler G.; Fink N.; Scarpatetti M.; Schippinger W.; Schmidt R.; Horvath A.; Dysbiosis, gut barrier dysfunction and inflammation in dementia: A pilot study. BMC Geriatr  2020,20(1),248","journal-title":"BMC Geriatr"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5056\/jnm17059","volume":"24","author":"Belei O.","year":"2018","unstructured":"Belei O.; Olariu L.; Dobrescu A.; Marcovici T.; Marginean O.; Is it useful to administer probiotics together with proton pump inhibitors in children with gastroesophageal reflux? J Neurogastroenterol Motil  2018,24(1),51-57","journal-title":"J Neurogastroenterol Motil"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"Imhann F.","year":"2016","unstructured":"Imhann F.; Bonder M.J.; Vich Vila A.; Fu J.; Mujagic Z.; Vork L.; Tigchelaar E.F.; Jankipersadsing S.A.; Cenit M.C.; Harmsen H.J.M.; Dijkstra G.; Franke L.; Xavier R.J.; Jonkers D.; Wijmenga C.; Weersma R.K.; Zhernakova A.; Proton pump inhibitors affect the gut microbiome. Gut  2016,65(5),740-748","journal-title":"Gut"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1038\/ctg.2015.20","volume":"6","author":"Tsuda A.","year":"2015","unstructured":"Tsuda A.; Suda W.; Morita H.; Takanashi K.; Takagi A.; Koga Y.; Hattori M.; Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol  2015,6(6),e89","journal-title":"Clin Transl Gastroenterol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/ijms21010323","volume":"21","author":"Vinke P.","year":"2020","unstructured":"Vinke P.; Wesselink E.; van Orten-Luiten W.; van Norren K.; The use of proton pump inhibitors may increase symptoms of muscle function loss in patients with chronic illnesses. Int J Mol Sci  2020,21(1),323","journal-title":"Int J Mol Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","volume":"27","author":"Zhou B.","year":"2016","unstructured":"Zhou B.; Huang Y.; Li H.; Sun W.; Liu J.; Proton-pump inhibitors and risk of fractures: An update meta-analysis. Osteoporos Int  2016,27(1),339-347","journal-title":"Osteoporos Int"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/jgh.13737","volume":"32","author":"Eusebi L.H.","year":"2017","unstructured":"Eusebi L.H.; Rabitti S.; Artesiani M.L.; Gelli D.; Montagnani M.; Zagari R.M.; Bazzoli F.; Proton pump inhibitors: Risks of long-term use. J Gastroenterol Hepatol  2017,32(7),1295-1302","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bcpt.13023","volume":"123","author":"Haastrup P.F.","year":"2018","unstructured":"Haastrup P.F.; Thompson W.; S\u00f8ndergaard J.; Jarb\u00f8l D.E.; Side effects of long-term proton pump inhibitor use: A review. Basic Clin Pharmacol Toxicol  2018,123(2),114-121","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/10408398.2018.1522613","volume":"60","author":"Gr\u00f6ber U.","year":"2020","unstructured":"Gr\u00f6ber U.; Schmidt J.; Kisters K.; Important drug-micronutrient interactions: A selection for clinical practice. Crit Rev Food Sci Nutr  2020,60(2),257-275","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11894-010-0141-0","volume":"12","author":"Ito T.","year":"2010","unstructured":"Ito T.; Jensen R.T.; Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep  2010,12(6),448-457","journal-title":"Curr Gastroenterol Rep"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/2042098613482484","volume":"4","author":"Heidelbaugh J.J.","year":"2013","unstructured":"Heidelbaugh J.J.; Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf  2013,4(3),125-133","journal-title":"Ther Adv Drug Saf"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5527\/wjn.v1.i6.151","volume":"1","author":"Florentin M.","year":"2012","unstructured":"Florentin M.; Elisaf M.S.; Proton pump inhibitor-induced hypomagnesemia: A new challenge. World J Nephrol  2012,1(6),151-154","journal-title":"World J Nephrol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"6907","DOI":"10.3748\/wjg.v23.i37.6907","volume":"23","author":"Semb S.","year":"2017","unstructured":"Semb S.; Helgstrand F.; Hj\u00f8rne F.; Bytzer P.; Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication. World J Gastroenterol  2017,23(37),6907-6910","journal-title":"World J Gastroenterol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"e13846","DOI":"10.1111\/apha.13846","volume":"235","author":"Gommers L.M.M.","year":"2022","unstructured":"Gommers L.M.M.; Hoenderop J.G.J.; de Baaij J.H.F.; Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol  2022,235(4),e13846","journal-title":"Acta Physiol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/lio2.515","volume":"6","author":"Gerges D.","year":"2021","unstructured":"Gerges D.; Grohmann N.; Trieu V.; Brundage W.; Sajisevi M.; Effect of  on symptomatic hypocalcemia after thyroidectomy: A retrospective cohort study. Laryngoscope Investig Otolaryngol  2021,6(1),150-154","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.3390\/jcm12082910","volume":"12","author":"Losurdo G.","year":"2023","unstructured":"Losurdo G.; Caccavo N.L.B.; Indellicati G.; Celiberto F.; Ierardi E.; Barone M.; Di Leo A.; Effect of long-term proton pump inhibitor use on blood vitamins and minerals: A primary care setting study. J Clin Med  2023,12(8),2910","journal-title":"J Clin Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/CIA.S27983","volume":"8","author":"Cardoso B.","year":"2013","unstructured":"Cardoso B.; Cominetti C.; Cozzolino S.M.; Importance and management of micronutrient deficiencies in patients with Alzheimer\u2019s disease. Clin Interv Aging  2013,8,531-542","journal-title":"Clin Interv Aging"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.3390\/molecules22101692","volume":"22","author":"Penke B.","year":"2017","unstructured":"Penke B.; Bog\u00e1r F.; F\u00fcl\u00f6p L.; \u03b2-amyloid and the pathomechanisms of alzheimer\u2019s disease: A comprehensive view. Molecules  2017,22(10),1692","journal-title":"Molecules"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","volume":"19","author":"Shin J.M.","year":"2013","unstructured":"Shin J.M.; Kim N.; Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil  2013,19(1),25-35","journal-title":"J Neurogastroenterol Motil"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"104606","DOI":"10.1016\/j.phrs.2019.104606","volume":"152","author":"Zhang H.J.","year":"2020","unstructured":"Zhang H.J.; Zhang X.H.; Liu J.; Sun L.N.; Shen Y.W.; Zhou C.; Zhang H.W.; Xie L.J.; Chen J.; Liu Y.; Wang Y.Q.; Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacol Res  2020,152,104606","journal-title":"Pharmacol Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/j.1440-1681.1995.tb02332.x","volume":"22","author":"van Driel I.R.","year":"1995","unstructured":"van Driel I.R.; Callaghan J.M.; Proton and potassium transport by H  \/K  -ATPases. Clin Exp Pharmacol Physiol  1995,22(12),952-960","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0014-5793(91)80091-G","volume":"278","author":"Modyanov N.N.","year":"1991","unstructured":"Modyanov N.N.; Petrukhin K.E.; Sverdlov V.E.; Grishin A.V.; Orlova M.Y.; Kostina M.B.; Makarevich O.I.; Broude N.E.; Monastyrskaya G.S.; Sverdlov E.D.; The family of human Na,K-ATPase genes ATP1AL1 gene is transcriptionally competent and probably encodes the related ion transport ATPase. FEBS Lett  1991,278(1),91-94","journal-title":"FEBS Lett"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1083\/jcb.201309130","volume":"203","author":"Wang D.","year":"2013","unstructured":"Wang D.; Hiesinger P.R.; The vesicular ATPase: A missing link between acidification and exocytosis. J Cell Biol  2013,203(2),171-173","journal-title":"J Cell Biol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.neuron.2010.12.012","volume":"68","author":"Tabares L.","year":"2010","unstructured":"Tabares L.; Betz B.; Multiple functions of the vesicular proton pump in nerve terminals. Neuron  2010,68(6),1020-1022","journal-title":"Neuron"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0021-9673(01)01225-0","volume":"949","author":"Cheng F.C.","year":"2002","unstructured":"Cheng F.C.; Ho Y.F.; Hung L.C.; Chen C.F.; Tsai T.H.; Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography. J Chromatogr A  2002,949(1-2),35-42","journal-title":"J Chromatogr A"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/0333102414535114","volume":"35","author":"Liang J. F.","year":"2015","unstructured":"Liang J. F.; Chen Y. T.; Fuh J. L.; Li S. Y.; Chen T. J.; Tang C. H.; Wang S. J.; Proton pump inhibitor-related headaches: A nationwide population-based case-crossover study in Taiwan. Cephalalgia  2015,35(3),203-210","journal-title":"Cephalalgia"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1046\/j.1365-2125.2000.00262.x","volume":"50","author":"Martin R.M.","year":"2000","unstructured":"Martin R.M.; Dunn N.R.; Freemantle S.; Shakir S.; The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: Cohort studies. Br J Clin Pharmacol  2000,50(4),366-372","journal-title":"Br J Clin Pharmacol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1167\/iovs.12-11091","volume":"54","author":"Hanneken A.M.","year":"2013","unstructured":"Hanneken A.M.; Babai N.; Thoreson W.B.; Oral proton pump inhibitors disrupt horizontal cell-cone feedback and enhance visual hallucinations in macular degeneration patients. Invest Ophthalmol Vis Sci  2013,54(2),1485-1489","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5009\/gnl16615","volume":"12","author":"Sandhu D.S.","year":"2018","unstructured":"Sandhu D.S.; Fass R.; Current trends in the management of gastroesophageal reflux disease. Gut Liver  2018,12(1),7-16","journal-title":"Gut Liver"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1715163517690745","volume":"150","author":"Duong S.","year":"2017","unstructured":"Duong S.; Patel T.; Chang F.; Dementia. Can Pharm J  2017,150(2),118-129","journal-title":"Can Pharm J"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"DeTure M.A.","year":"2019","unstructured":"DeTure M.A.; Dickson D.W.; The neuropathological diagnosis of alzheimer\u2019s disease. Mol Neurodegener  2019,14(1),32","journal-title":"Mol Neurodegener"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1586\/14737159.2015.1002469","volume":"15","author":"Reitz C.","year":"2015","unstructured":"Reitz C.; Genetic diagnosis and prognosis of alzheimer\u2019s disease: Challenges and opportunities. Expert Rev Mol Diagn  2015,15(3),339-348","journal-title":"Expert Rev Mol Diagn"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.expneurol.2015.05.006","volume":"272","author":"Venkat P.","year":"2015","unstructured":"Venkat P.; Chopp M.; Chen J.; Models and mechanisms of vascular dementia. Exp Neurol  2015,272,97-108","journal-title":"Exp Neurol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.bbadis.2016.01.015","volume":"1862","author":"Kalaria R.N.","year":"2016","unstructured":"Kalaria R.N.; Akinyemi R.; Ihara M.; Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta Mol Basis Dis  2016,1862(5),915-925","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"Outeiro T.F.","year":"2019","unstructured":"Outeiro T.F.; Koss D.J.; Erskine D.; Walker L.; Kurzawa-Akanbi M.; Burn D.; Donaghy P.; Morris C.; Taylor J.P.; Thomas A.; Attems J.; McKeith I.; Dementia with Lewy bodies: An update and outlook. Mol Neurodegener  2019,14(1),5","journal-title":"Mol Neurodegener"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"PCC.11r01190","DOI":"10.4088\/PCC.11r01190","volume":"13","author":"Zupancic M.","year":"2011","unstructured":"Zupancic M.; Mahajan A.; Handa K.; Dementia with lewy bodies: Diagnosis and management for primary care providers. Prim Care Companion CNS Disord  2011,13(5),PCC.11r01190","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00401-008-0460-5","volume":"117","author":"Mackenzie I.R.A.","year":"2009","unstructured":"Mackenzie I.R.A.; Neumann M.; Bigio E.H.; Cairns N.J.; Alafuzoff I.; Kril J.; Kovacs G.G.; Ghetti B.; Halliday G.; Holm I.E.; Ince P.G.; Kamphorst W.; Revesz T.; Rozemuller A.J.M.; Kumar-Singh S.; Akiyama H.; Baborie A.; Spina S.; Dickson D.W.; Trojanowski J.Q.; Mann D.M.A.; Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol  2009,117(1),15-18","journal-title":"Acta Neuropathol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s40264-018-0704-9","volume":"41","author":"Imfeld P.","year":"2018","unstructured":"Imfeld P.; Bodmer M.; Jick S.S.; Meier C.R.; Proton pump inhibitor use and risk of developing alzheimer\u2019s disease or vascular dementia: A case\u2013control analysis. Drug Saf  2018,41(12),1387-1396","journal-title":"Drug Saf"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1038\/ajg.2017.196","volume":"112","author":"Taipale H.","year":"2017","unstructured":"Taipale H.; Tolppanen A.M.; Tiihonen M.; Tanskanen A.; Tiihonen J.; Hartikainen S.; No association between proton pump inhibitor use and risk of alzheimer\u2019s disease. Am J Gastroenterol  2017,112(12),1802-1808","journal-title":"Am J Gastroenterol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/jgh.13750","volume":"32","author":"Batchelor R.","year":"2017","unstructured":"Batchelor R.; Gilmartin J.F.M.; Kemp W.; Hopper I.; Liew D.; Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. J Gastroenterol Hepatol  2017,32(8),1426-1435","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/5257285","volume":"2018","author":"Ortiz-Guerrero G.","year":"2018","unstructured":"Ortiz-Guerrero G.; Amador-Mu\u00f1oz D.; Calder\u00f3n-Ospina C.A.; L\u00f3pez-Fuentes D.; Nava Mesa M.O.; Proton pump inhibitors and dementia: Physiopathological mechanisms and clinical consequences. Neural Plast  2018,2018,1-9","journal-title":"Neural Plast"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5056\/jnm18001","volume":"24","author":"Kinoshita Y.","year":"2018","unstructured":"Kinoshita Y.; Ishimura N.; Ishihara S.; Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil  2018,24(2),182-196","journal-title":"J Neurogastroenterol Motil"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"Katz P.O.","year":"2022","unstructured":"Katz P.O.; Dunbar K.B.; Schnoll-Sussman F.H.; Greer K.B.; Yadlapati R.; Spechler S.J.; ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol  2022,117(1),27-56","journal-title":"Am J Gastroenterol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41392-022-01251-0","volume":"7","author":"Guo J.","year":"2022","unstructured":"Guo J.; Huang X.; Dou L.; Yan M.; Shen T.; Tang W.; Li J.; Aging and aging-related diseases: From molecular mechanisms to interventions and treatments. Signal Transduct Target Ther  2022,7(1),391","journal-title":"Signal Transduct Target Ther"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.3390\/jcm12134274","volume":"12","author":"Khan Z.","year":"2023","unstructured":"Khan Z.; Gupta G.D.; Mehan S.; Cellular and molecular evidence of multiple sclerosis diagnosis and treatment challenges. J Clin Med  2023,12(13),4274","journal-title":"J Clin Med"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.mayocp.2020.07.033","volume":"96","author":"Pataky M.W.","year":"2021","unstructured":"Pataky M.W.; Young W.F.; Nair K.S.; Hormonal and metabolic changes of aging and the influence of lifestyle modifications. Mayo Clin Proc  2021,96(3),788-814","journal-title":"Mayo Clin Proc"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10522-023-10034-1","volume":"24","author":"Prajapati A.","year":"2023","unstructured":"Prajapati A.; Mehan S.; Khan Z.; The role of Smo-Shh\/Gli signaling activation in the prevention of neurological and ageing disorders. Biogerontology  2023,24(4),493-531","journal-title":"Biogerontology"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1053\/j.gastro.2017.06.061","volume":"153","author":"Lochhead P.","year":"2017","unstructured":"Lochhead P.; Hagan K.; Joshi A.D.; Khalili H.; Nguyen L.H.; Grodstein F.; Chan A.T.; Association between proton pump inhibitor use and cognitive function in women. Gastroenterology  2017,153(4),971-979.e4","journal-title":"Gastroenterology"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"109","DOI":"10.14336\/AD.2014.0305","volume":"6","author":"Bonomini F.","year":"2015","unstructured":"Bonomini F.; Rodella L.F.; Rezzani R.; Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis  2015,6(2),109-120","journal-title":"Aging Dis"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3389\/fneur.2018.01142","volume":"9","author":"Novotny M.","year":"2019","unstructured":"Novotny M.; Klimova B.; Valis M.; PPI long term use: Risk of neurological adverse events? Front Neurol  2019,9,1142","journal-title":"Front Neurol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.3390\/nu13124337","volume":"13","author":"Cristina N.M.","year":"2021","unstructured":"Cristina N.M.; Lucia A.; Nutrition and healthy aging: Prevention and treatment of gastrointestinal diseases. Nutrients  2021,13(12),4337","journal-title":"Nutrients"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/pds.2026","volume":"19","author":"Chiu H.F.","year":"2010","unstructured":"Chiu H.F.; Huang Y.W.; Chang C.C.; Yang C.Y.; Use of proton pump inhibitors increased the risk of hip fracture: A population-based case\u2013control study. Pharmacoepidemiol Drug Saf  2010,19(11),1131-1136","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1370\/afm.983","volume":"7","author":"Valderas J.M.","year":"2009","unstructured":"Valderas J.M.; Starfield B.; Sibbald B.; Salisbury C.; Roland M.; Defining comorbidity: Implications for understanding health and health services. Ann Fam Med  2009,7(4),357-363","journal-title":"Ann Fam Med"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4103\/picr.PICR_132_16","volume":"8","author":"Khandeparkar A.","year":"2017","unstructured":"Khandeparkar A.; Rataboli P.; A study of harmful drug\u2013drug interactions due to polypharmacy in hospitalized patients in goa medical college. Perspect Clin Res  2017,8(4),180-186","journal-title":"Perspect Clin Res"},{"key":"ref=106","author":"Varghese D.","year":"2022","unstructured":"Varghese D.; Ishida C.; Haseer Koya H.; Polypharmacy. StatPearls  2022","journal-title":"StatPearls"},{"key":"ref=107","first-page":"601","volume":"18","author":"Palleria C.","year":"2013","unstructured":"Palleria C.; Di Paolo A.; Giofr\u00e8 C.; Caglioti C.; Leuzzi G.; Siniscalchi A.; De Sarro G.; Gallelli L.; Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci  2013,18(7),601-610","journal-title":"J Res Med Sci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","volume":"37","author":"Wedemeyer R.S.","year":"2014","unstructured":"Wedemeyer R.S.; Blume H.; Pharmacokinetic drug interaction profiles of proton pump inhibitors: An update. Drug Saf  2014,37(4),201-211","journal-title":"Drug Saf"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"100880","DOI":"10.1016\/j.esmoop.2023.100880","volume":"8","author":"Raoul J.L.","year":"2023","unstructured":"Raoul J.L.; Moreau-Bachelard C.; Gilabert M.; Edeline J.; Fr\u00e9nel J.S.; Drug\u2013drug interactions with proton pump inhibitors in cancer patients: An underrecognized cause of treatment failure. ESMO Open  2023,8(1),100880","journal-title":"ESMO Open"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/17425255.2022.2098107","volume":"18","author":"Ben Ghezala I.","year":"2022","unstructured":"Ben Ghezala I.; Luu M.; Bardou M.; An update on drug\u2013drug interactions associated with proton pump inhibitors. Expert Opin Drug Metab Toxicol  2022,18(5),337-346","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/medicina56070320","volume":"56","author":"B\u0142eszy\u0144ska E.","year":"2020","unstructured":"B\u0142eszy\u0144ska E.; Wierucki \u0141.; Zdrojewski T.; Renke M.; Pharmacological interactions in the elderly. Medicina  2020,56(7),320","journal-title":"Medicina"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"459","DOI":"10.7861\/clinmedicine.16-5-459","volume":"16","author":"Maxwell S.R.J.","year":"2016","unstructured":"Maxwell S.R.J.; Rational prescribing: The principles of drug selection. Clin Med  2016,16(5),459-464","journal-title":"Clin Med"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2042098617736192","volume":"9","author":"Garfinkel D.","year":"2018","unstructured":"Garfinkel D.; Poly-de-prescribing to treat polypharmacy: Efficacy and safety. Ther Adv Drug Saf  2018,9(1),25-43","journal-title":"Ther Adv Drug Saf"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","volume":"322","author":"Chen T.K.","year":"2019","unstructured":"Chen T.K.; Knicely D.H.; Grams M.E.; Chronic kidney disease diagnosis and management. JAMA  2019,322(13),1294-1304","journal-title":"JAMA"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/2040622315569501","volume":"6","author":"Kang J.H.E.","year":"2015","unstructured":"Kang J.H.E.; Kang J.Y.; Lifestyle measures in the management of gastro-oesophageal reflux disease: Clinical and pathophysiological considerations. Ther Adv Chronic Dis  2015,6(2),51-64","journal-title":"Ther Adv Chronic Dis"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1586\/ecp.09.8","volume":"2","author":"Mejia A.","year":"2009","unstructured":"Mejia A.; Kraft W.K.; Acid peptic diseases: Pharmacological approach to treatment. Expert Rev Clin Pharmacol  2009,2(3),295-314","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bpg.2013.06.005","volume":"27","author":"Kahrilas P.J.","year":"2013","unstructured":"Kahrilas P.J.; Boeckxstaens G.; Smout A.J.P.M.; Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol  2013,27(3),401-414","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref=118","first-page":"354","volume":"63","author":"Farrell B.","year":"2017","unstructured":"Farrell B.; Pottie K.; Thompson W.; Boghossian T.; Pizzola L.; Rashid F.J.; Rojas-Fernandez C.; Walsh K.; Welch V.; Moayyedi P.; Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician  2017,63(5),354-364","journal-title":"Can Fam Physician"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1218506","DOI":"10.3389\/fphar.2023.1218506","volume":"14","author":"Gumbar S.","year":"2023","unstructured":"Gumbar S.; Bhardwaj S.; Mehan S.; Khan Z.; Narula A.S.; Kalfin R.; Tabrez S.; Zughaibi T.A.; Wasi S.; Renal mitochondrial restoration by gymnemic acid in gentamicin-mediated experimental nephrotoxicity: evidence from serum, kidney and histopathological alterations. Front Pharmacol  2023,14,1218506","journal-title":"Front Pharmacol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5001\/omj.2011.38","volume":"26","author":"Jimmy B.","year":"2011","unstructured":"Jimmy B.; Jose J.; Patient medication adherence: Measures in daily practice. Oman Med J  2011,26(3),155-159","journal-title":"Oman Med J"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3390\/jcm8122162","volume":"8","author":"Douwes R.M.","year":"2019","unstructured":"Douwes R.M.; Gomes-Neto A.W.; Schutten J.C.; van den Berg E.; de Borst M.H.; Berger S.P.; Touw D.J.; Hak E.; Blokzijl H.; Navis G.; Bakker S.J.L.; Proton-pump inhibitors and hypomagnesaemia in kidney transplant recipients. J Clin Med  2019,8(12),2162","journal-title":"J Clin Med"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","volume":"14","author":"Scarpignato C.","year":"2016","unstructured":"Scarpignato C.; Gatta L.; Zullo A.; Blandizzi C.; Effective and safe proton pump inhibitor therapy in acid-related diseases \u2013 A position paper addressing benefits and potential harms of acid suppression. BMC Med  2016,14(1),179","journal-title":"BMC Med"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"511S","DOI":"10.1093\/advances\/nmy023","volume":"9","author":"Miller J.W.","year":"2018","unstructured":"Miller J.W.; Proton pump inhibitors, H2-receptor antagonists, metformin, and vitamin B-12 deficiency: Clinical implications. Adv Nutr  2018,9(4),511S-518S","journal-title":"Adv Nutr"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"21046","DOI":"10.1038\/s41598-020-78199-0","volume":"10","author":"Torres-Bondia F.","year":"2020","unstructured":"Torres-Bondia F.; Dakterzada F.; Galv\u00e1n L.; Buti M.; Besanson G.; Gill E.; Buil R.; de Batlle J.; Pi\u00f1ol-Ripoll G.; Proton pump inhibitors and the risk of alzheimer\u2019s disease and non-alzheimer\u2019s dementias. Sci Rep  2020,10(1),21046","journal-title":"Sci Rep"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40264-018-0638-2","volume":"41","author":"Park S.K.","year":"2018","unstructured":"Park S.K.; Baek Y.H.; Pratt N.; Kalisch Ellett L.; Shin J.Y.; The uncertainty of the association between proton pump inhibitor use and the risk of dementia: Prescription sequence symmetry analysis using a korean healthcare database between 2002 and 2013. Drug Saf  2018,41(6),615-624","journal-title":"Drug Saf"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"8271","DOI":"10.3390\/ijerph17218271","volume":"17","author":"Chen L.Y.","year":"2020","unstructured":"Chen L.Y.; Lin H.J.; Wu W.T.; Chen Y.C.; Chen C.L.; Kao J.; You S.L.; Chou Y.C.; Sun C.A.; Clinical use of acid suppressants and risk of dementia in the elderly: A pharmaco-epidemiological cohort study. Int J Environ Res Public Health  2020,17(21),8271","journal-title":"Int J Environ Res Public Health"},{"key":"ref=127","first-page":"S27","volume":"36","author":"Welu J.","year":"2019","unstructured":"Welu J.; Metzger J.; Bebensee S.; Ahrendt A.; Vasek M.; Proton pump inhibitor use and risk of dementia in the veteran population. Federal practitioner: For the health care professionals of the VA. DoD, and PHS  2019,36(Suppl. 4),S27-S31","journal-title":"DoD, and PHS"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/cpt.1430","volume":"106","author":"Huang S.T.","year":"2019","unstructured":"Huang S.T.; Tseng L.Y.; Chen L.K.; Peng L.N.; Hsiao F.Y.; Does long-term proton pump inhibitor use increase risk of dementia? not really! results of the group-based trajectory analysis. Clin Pharmacol Ther  2019,106(3),616-622","journal-title":"Clin Pharmacol Ther"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","volume":"157","author":"Moayyedi P.","year":"2019","unstructured":"Moayyedi P.; Eikelboom J.W.; Bosch J.; Connolly S.J.; Dyal L.; Shestakovska O.; Leong D.; Anand S.S.; St\u00f6rk S.; Branch K.R.H.; Bhatt D.L.; Verhamme P.B.; O\u2019Donnell M.; Maggioni A.P.; Lonn E.M.; Piegas L.S.; Ertl G.; Keltai M.; Bruns N.C.; Muehlhofer E.; Dagenais G.R.; Kim J.H.; Hori M.; Steg P.G.; Hart R.G.; Diaz R.; Alings M.; Widimsky P.; Avezum A.; Probstfield J.; Zhu J.; Liang Y.; Lopez-Jaramillo P.; Kakkar A.K.; Parkhomenko A.N.; Ryden L.; Pogosova N.; Dans A.L.; Lanas F.; Commerford P.J.; Torp-Pedersen C.; Guzik T.J.; Vinereanu D.; Tonkin A.M.; Lewis B.S.; Felix C.; Yusoff K.; Metsarinne K.P.; Fox K.A.A.; Yusuf S.; Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology  2019,157(3),682-691.e2","journal-title":"Gastroenterology"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.cgh.2018.01.034","volume":"16","author":"Wod M.","year":"2018","unstructured":"Wod M.; Hallas J.; Andersen K.; Garc\u00eda Rodr\u00edguez L. A.; Christensen K.; Gaist D.; Lack of association between proton pump inhibitor use and cognitive decline. Clin Gastroenterol Hepatol  2018,16(5),681-689","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1111\/jgs.14956","volume":"65","author":"Goldstein F.C.","year":"2017","unstructured":"Goldstein F.C.; Steenland K.; Zhao L.; Wharton W.; Levey A.I.; Hajjar I.; Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc  2017,65(9),1969-1974","journal-title":"J Am Geriatr Soc"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"671","DOI":"10.14309\/ajg.0000000000000500","volume":"115","author":"Khan M.A.","year":"2020","unstructured":"Khan M.A.; Yuan Y.; Iqbal U.; Kamal S.; Khan M.; Khan Z.; Lee W.M.; Howden C.W.; No association linking short-term proton pump inhibitor use to dementia: Systematic review and meta-analysis of observational studies. Am J Gastroenterol  2020,115(5),671-678","journal-title":"Am J Gastroenterol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"CD002095","DOI":"10.1002\/14651858.CD002095.pub5","volume":"2013","author":"Sigterman K.E.","year":"2013","unstructured":"Sigterman K.E.; van Pinxteren B.; Bonis P.A.; Lau J.; Numans M.E.; Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Libr  2013,2013(5),CD002095","journal-title":"Cochrane Libr"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/cns.13035","volume":"24","author":"Adlimoghaddam A.","year":"2018","unstructured":"Adlimoghaddam A.; Neuendorff M.; Roy B.; Albensi B.C.; A review of clinical treatment considerations of donepezil in severe alzheimer\u2019s disease. CNS Neurosci Ther  2018,24(10),876-888","journal-title":"CNS Neurosci Ther"},{"key":"ref=135","first-page":"303","volume":"3","author":"Cacabelos R.","year":"2007","unstructured":"Cacabelos R.; Donepezil in alzheimer\u2019s disease: From conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat  2007,3(3),303-333","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/2042098617750555","volume":"9","author":"Khoury R.","year":"2018","unstructured":"Khoury R.; Rajamanickam J.; Grossberg G.T.; An update on the safety of current therapies for Alzheimer\u2019s disease: Focus on rivastigmine. Ther Adv Drug Saf  2018,9(3),171-178","journal-title":"Ther Adv Drug Saf"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"CD001191","DOI":"10.1002\/14651858.CD001191.pub4","volume":"9","author":"Birks J.S.","year":"2015","unstructured":"Birks J.S.; Chong L.Y.; Grimley Evans J.; Rivastigmine for alzheimer\u2019s disease. Cochrane Libr  2015,9(9),CD001191","journal-title":"Cochrane Libr"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2165\/00002512-200926030-00004","volume":"26","author":"Aronson S.","year":"2009","unstructured":"Aronson S.; Van Baelen B.; Kavanagh S.; Schwalen S.; Optimal dosing of galantamine in patients with mild or moderate alzheimer\u2019s disease: Post Hoc analysis of a randomized, double-blind, placebo-controlled trial. Drugs Aging  2009,26(3),231-239","journal-title":"Drugs Aging"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1517\/17425251003592137","volume":"6","author":"Prvulovic D.","year":"2010","unstructured":"Prvulovic D.; Hampel H.; Pantel J.; Galantamine for alzheimer\u2019s disease. Expert Opin Drug Metab Toxicol  2010,6(3),345-354","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","volume":"9","author":"Emre M.","year":"2010","unstructured":"Emre M.; Tsolaki M.; Bonuccelli U.; Dest\u00e9e A.; Tolosa E.; Kutzelnigg A.; Ceballos-Baumann A.; Zdravkovic S.; Bladstr\u00f6m A.; Jones R.; Memantine for patients with parkinson\u2019s disease dementia or dementia with Lewy bodies: A randomised, double-blind, placebo-controlled trial. Lancet Neurol  2010,9(10),969-977","journal-title":"Lancet Neurol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s11940-013-0261-6","volume":"15","author":"Boot B.P.","year":"2013","unstructured":"Boot B.P.; McDade E.M.; McGinnis S.M.; Boeve B.F.; Treatment of dementia with lewy bodies. Curr Treat Options Neurol  2013,15(6),738-764","journal-title":"Curr Treat Options Neurol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"CD003154","DOI":"10.1002\/14651858.CD003154.pub6","volume":"3","author":"McShane R.","year":"2019","unstructured":"McShane R.; Westby M.J.; Roberts E.; Minakaran N.; Schneider L.; Farrimond L.E.; Maayan N.; Ware J.; Debarros J.; Memantine for dementia. Cochrane Libr  2019,3(3),CD003154","journal-title":"Cochrane Libr"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"CD003158","DOI":"10.1002\/14651858.CD003158","volume":"2003","author":"Hudson S.A.","year":"2003","unstructured":"Hudson S.A.; Tabet N.; Acetyl-l-carnitine for dementia. Cochrane Libr  2003,2003(2),CD003158","journal-title":"Cochrane Libr"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jpsychires.2014.02.005","volume":"53","author":"Wang S.M.","year":"2014","unstructured":"Wang S.M.; Han C.; Lee S.J.; Patkar A.A.; Masand P.S.; Pae C.U.; A review of current evidence for acetyl-l-carnitine in the treatment of depression. J Psychiatr Res  2014,53,30-37","journal-title":"J Psychiatr Res"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3390\/nu12051389","volume":"12","author":"Pennisi M.","year":"2020","unstructured":"Pennisi M.; Lanza G.; Cantone M.; D\u2019Amico E.; Fisicaro F.; Puglisi V.; Vinciguerra L.; Bella R.; Vicari E.; Malaguarnera G.; Acetyl-L-carnitine in dementia and other cognitive disorders: A critical update. Nutrients  2020,12(5),1389","journal-title":"Nutrients"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"363985","DOI":"10.1155\/2014\/363985","author":"Xing S. H.","year":"2014","unstructured":"Xing S. H.; Zhu C. X.; Zhang R.; An L.; Huperzine a in the treatment of alzheimer's disease and vascular dementia: A meta-analysis. Evid Based Complement  Altern Med  2014,363985","journal-title":"Evid Based Complement  Altern Med"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"CD007365","DOI":"10.1002\/14651858.CD007365.pub2","author":"Hao Z.","year":"2009","unstructured":"Hao Z.; Liu M.; Liu Z.; Lu D.H.; Huperzine A for vascular dementia. Cochrane Libr  2009(2),CD007365","journal-title":"Cochrane Libr"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/01.JGP.0000196628.12010.35","volume":"14","author":"Tariot P. N.","year":"2006","unstructured":"Tariot P. N.; Schneider L.; Katz I. R.; Mintzer J. E.; Street J.; Copenhaver M.; Williams-Hughes C.; Quetiapine treatment of psychosis associated with dementia: A double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatr  2006,14(9),767-776","journal-title":"Am J Geriatr Psychiatr"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/156720507779939805","volume":"4","author":"Zhong K.","year":"2007","unstructured":"Zhong K.; Tariot P.; Mintzer J.; Minkwitz M.; Devine N.; Quetiapine to treat agitation in dementia: A randomized, double-blind, placebo-controlled study. Curr Alzheimer Res  2007,4(1),81-93","journal-title":"Curr Alzheimer Res"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/9343514","volume":"2022","author":"Beshir S.A.","year":"2022","unstructured":"Beshir S.A.; Aadithsoorya A.M.; Parveen A.; Goh S.S.L.; Hussain N.; Menon V.B.; Aducanumab therapy to treat alzheimer\u2019s disease: A narrative review. Int J Alzheimers Dis  2022,2022,1-10","journal-title":"Int J Alzheimers Dis"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","volume":"2","author":"Ferrero J.","year":"2016","unstructured":"Ferrero J.; Williams L.; Stella H.; Leitermann K.; Mikulskis A.; O\u2019Gorman J.; Sevigny J.; First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease. Alzheimers Dement  2016,2(3),169-176","journal-title":"Alzheimers Dement"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"van Dyck C.H.","year":"2023","unstructured":"van Dyck C.H.; Swanson C.J.; Aisen P.; Bateman R.J.; Chen C.; Gee M.; Kanekiyo M.; Li D.; Reyderman L.; Cohen S.; Froelich L.; Katayama S.; Sabbagh M.; Vellas B.; Watson D.; Dhadda S.; Irizarry M.; Kramer L.D.; Iwatsubo T.; Lecanemab in early alzheimer\u2019s disease. N Engl J Med  2023,388(1),9-21","journal-title":"N Engl J Med"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"McDade E.","year":"2022","unstructured":"McDade E.; Cummings J.L.; Dhadda S.; Swanson C.J.; Reyderman L.; Kanekiyo M.; Koyama A.; Irizarry M.; Kramer L.D.; Bateman R.J.; Lecanemab in patients with early Alzheimer\u2019s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther  2022,14(1),191","journal-title":"Alzheimers Res Ther"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","volume":"28","author":"Grossberg G. T.","year":"2020","unstructured":"Grossberg G. T.; Kohegyi E.; Mergel V.; Josiassen M. K.; Meulien D.; Hobart M.; Slomkowski M.; Baker R. A.; McQuade R. D.; Cummings J. L.; Efficacy and safety of brexpiprazole for the treatment of agitation in alzheimer's dementia: Two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatr  2020,28(4),383-400","journal-title":"Am J Geriatr Psychiatr"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2217\/nmt-2020-0013","volume":"10","author":"Stummer L.","year":"2020","unstructured":"Stummer L.; Markovic M.; Maroney M.; Brexpiprazole in the treatment of schizophrenia and agitation in alzheimer\u2019s disease. Neurodegener Dis Manag  2020,10(4),205-217","journal-title":"Neurodegener Dis Manag"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"547","DOI":"10.9758\/cpn.2019.17.4.547","volume":"17","author":"Hanazawa T.","year":"2019","unstructured":"Hanazawa T.; Kamijo Y.; Effect of suvorexant on nocturnal delirium in elderly patients with alzheimer's disease: A case-series study. Clin Psychopharmacol Neurosci  2019,17(4),547-550","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/alz.12035","volume":"16","author":"Herring W.J.","year":"2020","unstructured":"Herring W.J.; Ceesay P.; Snyder E.; Bliwise D.; Budd K.; Hutzelmann J.; Stevens J.; Lines C.; Michelson D.; Polysomnographic assessment of suvorexant in patients with probable alzheimer\u2019s disease dementia and insomnia: A randomized trial. Alzheimers Dement  2020,16(3),541-551","journal-title":"Alzheimers Dement"}],"container-title":["Current Alzheimer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672050289946240223050737","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/227484\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672050289946240223050737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T10:17:58Z","timestamp":1715077078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/227484\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":157,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115672050289946240223050737","relation":{},"ISSN":["1567-2050"],"issn-type":[{"value":"1567-2050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}